361 Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

361 Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19,040	Closed	-$1.63M	–	333
2018 Q3	$1.63M	Buy	19,040 +4,172	+28%	+$418K	0.35%	151
2018 Q2	$1.72M	Sell	14,868 -3,903	-21%	-$389K	0.39%	90
2018 Q1	$1.52M	Buy	+18,771	New	+$1.44M	0.38%	109

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

361 Capital's ENTA Position: Q4 2018 in Review

361 Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 19,040 shares — an estimated $1.63M sold.

361 Capital first reported a position in ENTA in Q1 2018 and held it in 3 quarters. The position peaked at $1.72M in Q2 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

361 Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
361 Capital sold 19,040 Enanta Pharmaceuticals shares in Q4 2018, an estimated $1.63M.
361 Capital first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 3 quarters.
361 Capital's Enanta Pharmaceuticals position peaked at $1.72M in Q2 2018.
183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.